ALNY Q2 2017 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+82.9% YoY

Gross Profit

$16M100.0% margin

Operating Income

-$120M-756.2% margin

Net Income

-$118M-743.3% margin

EPS (Diluted)

$-1.34

QoQ Revenue Growth

-16.0%

Cash Flow

Operating Cash Flow

-$81M

Free Cash Flow

-$103M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$311M

Stockholders' Equity

$1.1B

Cash & Equivalents

$409M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$9M	+82.9%
Gross Profit	$16M	$9M	+82.9%
Operating Income	-$120M	-$92M	-30.3%
Net Income	-$118M	-$90M	-31.4%